CSI Market
Sign In | Register

Blueprint Medicines (BPMC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BPMC quarterly Cash Flow →
This page allows investors to follow Blueprint Medicines's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-67.09
Depreciation & amortization16.29
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-4.03
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation108.91
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-173.68
Increase Decrease In Contract With Customer Liability-0.41
Accretion Of Premiums And Discounts On Investments-
Lease Right Of Use Asset Amortization9.93
Noncash Interest Expense1.18
Increase Decrease In Contract With Customer Liability And Other Noncurrent Liabilities0.15
Increase Decrease In Operating Lease Liability-
Income taxes-0.98
Realized Investment Gains (Losses), Total0.00
Increase (Decrease) in Accounts Receivable-32.85
Increase (Decrease) in Accounts Payable2.20
Increase (Decrease) in Accrued Liabilities8.21
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.63
Other Working Capital-23.36
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-34.43
Discontinued operations0.00
Net Cash flow from Operating Activities-192.59
Investing Activities
Capital Expenditures-4.63
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities923.56
Payments to Acquire Available-for-sale Securities, Debt-966.43
Real Estate Investments0.00
Proceeds From Sale Of Equity Securities Without Readily Determinable Fair Value Investing Activities-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-47.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments146.43
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-33.01
Payment Of Offering Costs-
Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan77.74
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents81.52
Capital Expenditures Incurred But Not Yet Paid0.43
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities273.11
Effect of exchange rate on cash flow-0.91
Discontinued operations0.00
Free Cash Flow-197.22
Total Cash Flow33.02
4 historic quarters locked

Sign in to unlock the full Blueprint Medicines cash flow history.

Sign In Create Free Account

About Blueprint Medicines Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-25-000953

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License